^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    DetermaIO™

    Company:
    Oncocyte
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Sensitive: C3 – Early Trials

    [PD-L1 negative-Triple Negative Breast Cancer-pembrolizumab]

    Source:
    ASCO 2022
    Test:

    DetermaIO™

    Title:
    Association of 27-gene IO score with outcome in a phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in metastatic triple-negative breast cancer (mTNBC)
    Published date:
    05/26/2022
    Excerpt:
    PD-L1-/IO+ tumors constituted 31% (n = 5/16) of PD-L1- cases and exhibited favorable outcome (ORR 40%, mPFS 162d, mOS 556d). IO score and ORR varied across TNBCtype classifications (BL1 subtype: 50% ORR, 66% IO+; BL2 subtype: 0% ORR, 66% IO+; LAR subtype: 50% ORR, 0% IO+, MSL subtype: 33% ORR, 60% IO+). IO score is associated with favorable outcome following pembro + CT, and may identify PD-L1-negative cases that respond to pembro + CT.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.2022.40.16_suppl.1082
    Trial ID:
    NCT02734290